Elon Musk Says Neuralink Will Start Implanting Brain Chips in Humans

If you’ve been following Elon Musk technology news, Neuralink has probably shown up in your feed more than once this year. Between human trials, a surgical robot announcement, and a shift toward mass production, things are moving fast. But what’s actually happening — and what does it mean for the people involved? Here’s an honest look at where the Neuralink brain chip stands in 2026.

What Is Neuralink, and How Does It Work?

Neuralink is a neurotechnology company Elon Musk co-founded in 2016. Its main product is a brain computer interface — a small implant, roughly the size of a coin, that sits inside the skull and reads electrical signals from the brain. Those signals get translated into digital commands, letting a person control a computer, cursor, or external device using only their thoughts.

The N1 implant has 64 ultra-thin threads extending from the chip into brain tissue, each carrying 16 electrodes. That gives the device 1,024 electrode contact points in total. All data is transmitted wirelessly via Bluetooth to external devices, and the chip sits flush with the skull — no external wires or ports.

For several years, Neuralink ran animal studies before applying for FDA approval to begin human trials. The FDA initially rejected that application in 2022, then approved it in 2023. Human trials began in January 2024, and the results so far have been closely watched by the medical and neuroscience communities alike.

The First Human Patient and What He Experienced

The first person to receive the Neuralink brain chip was Noland Arbaugh, a 29-year-old Texan who had been paralyzed from the shoulders down since 2016 following a diving accident. He enrolled in the trial saying he had “nothing to lose,” and his surgery took place at the Barrow Neurological Institute in Phoenix.

The experience wasn’t without problems. About a month after surgery, roughly 85% of his electrode threads retracted from the brain tissue, sharply reducing the device’s performance. Neuralink chose not to operate again — instead, the team pushed software updates that partially made up for the lost thread connections. It worked well enough to restore meaningful function, but the incident raised fair questions about how durable these implants are over time.

Neuralink has since redesigned the thread architecture, making them thinner to reduce the tissue displacement that likely caused the retraction. A subsequent patient in the UK reportedly gained computer control within hours of surgery using this updated design — a meaningful improvement over the weeks of calibration Arbaugh needed after his implant.

2026: Mass Production and Automated Surgery

One of the biggest shifts in recent Elon Musk technology news around Neuralink is the move toward high-volume production. On New Year’s Eve 2025, Musk posted on X that Neuralink would “start high-volume production of brain-computer interface devices and move to a streamlined, almost entirely automated surgical procedure in 2026.”

The surgery itself has also changed in a meaningful way. Previously, inserting the device required removing a small section of the skull before a robotic arm threaded the electrodes into brain tissue. The updated procedure lets the device threads pass through the dura — the tough protective membrane around the brain — without removing it. Musk described that specific change as “a big deal,” and from a surgical risk standpoint, it genuinely is. Fewer steps in the procedure means fewer chances for complications.

In May 2026, Neuralink announced it was building a next-generation surgical robot capable of reaching any part of the brain — not just the motor cortex targeted in current trials. The long-term goal described by the company is a “generalised neural interface” that could potentially help with conditions well beyond paralysis, including Parkinson’s disease, epilepsy, and sensory disorders.

The company raised $650 million in a Series E funding round in June 2025, backing the manufacturing scale-up and broader clinical expansion. Phase 3 trials are expected later in 2026, with the company targeting FDA premarket approval in 2027 and commercial availability for paralysis patients around 2028.

Blindsight: A Device to Restore Vision

The Neuralink brain chip isn’t the only device the company is working on. Blindsight is a separate implant designed to give some form of vision back to people who are completely blind — even those born without sight. It would be placed in the visual cortex and connected wirelessly to an external camera, bypassing the eyes entirely and sending visual information straight to the brain.

Musk has been honest that early versions will produce low-resolution, pixelated perception — he compared early results to old Atari graphics rather than normal eyesight. The expectation is that the brain adapts over time and the quality of perceived vision improves with use.

Blindsight has received FDA Breakthrough Device designation, which speeds up the review process without guaranteeing approval. Human trials are planned for 2026. Neuralink has also received a separate Breakthrough Device designation for speech restoration technology, aimed at people who have lost the ability to speak due to ALS, stroke, cerebral palsy, or multiple sclerosis.

What Experts Think — and Where They Push Back

The scientific community has a genuinely mixed take on Neuralink’s work. Some of the foundational brain computer interface research was done nearly two decades ago at institutions like Duke and the University of Pittsburgh, so the core science isn’t new. Miguel Nicolelis, a neuroscientist at Duke, has argued publicly that the company overstates its novelty and doesn’t give enough attention to the ethical and surgical challenges involved. Some competitors in the BCI space have also suggested that Musk’s tendency to make sweeping statements about AI implants in humans — including his longer-term comments about merging human consciousness with artificial intelligence — actually makes it harder for the field to have serious medical conversations.

Those criticisms are fair. At the same time, the clinical results from 21 patients are real. Arbaugh’s long-term daily use data, shared publicly at conferences, gives researchers the kind of operational information that controlled lab settings simply can’t produce. Both things can be true: the near-term medical results are genuine, and the further-out claims about future technology innovations deserve careful, skeptical evaluation.

Privacy and Ethics: Real Questions That Need Real Answers

As AI implants in humans move from theory to reality, data privacy becomes a concrete concern. Neural data is more personal than anything stored on a phone — it reflects thoughts, intentions, and cognitive patterns. In 2025, U.S. senators introduced the MIND Act, which classifies neural data as sensitive, requires informed consent, and prohibits its sale. Several states have extended existing biometric privacy laws to cover neurotechnology as well.

Neuralink states that patients own their own brain data, uses end-to-end encryption, and has built in a pause-logging feature. Those are reasonable baseline protections. But as the technology scales from 21 patients toward thousands — and eventually, if Musk’s longer-range vision is pursued, toward healthy individuals — the ethical and legal frameworks will need to keep pace with the technology, not trail behind it.

For now, the most important story is a simple one: a 31-year-old man paralyzed from the shoulders down is studying neuroscience, earning top grades, and managing his own daily life using a chip in his skull. That’s what the Neuralink brain chip actually looks like in 2026. Everything beyond that is still being written.

Frequently Asked Questions

How many people currently have the Neuralink implant?

At least 21 people worldwide are enrolled in the PRIME Study as of early 2026, all with severe paralysis or ALS. Trial sites are active in the US, Canada, UK, and UAE.

Is the Neuralink brain chip FDA approved?

Not commercially. It runs under FDA approval for clinical trials. Blindsight and the speech restoration technology have both received FDA Breakthrough Device designation, which speeds up review but is not the same as approval.

What are the risks?

Standard surgical risks apply. One early patient saw 85% of electrode threads retract, reducing performance — resolved through software updates and a redesigned thread architecture. No major safety incidents have been reported across all 21 patients.

When will it be commercially available?

Neuralink is targeting FDA premarket approval in 2027 and commercial availability for paralysis patients around 2028, pending Phase 3 trials expected to begin later in 2026.